Likelihood and Outcomes of Heart Failure With Nonreduced Ejection Fraction Among Patients With Negative Cardiac Amyloidosis Screening.
Dal Soglio Solenn S, Beaulieu Marie-Claude MC, Lucinian Yousif A YA, Moazzami Chloé C et al.
Heart failure with nonreduced ejection fraction (HFnrEF) is a clinically heterogeneous condition leading to diagnostic challenges. Identifying populations with a higher likelihood of HFnrEF may increase diagnostic efficiency and translate into earlier appropriate care. We conducted a retrospective cohort analysis of adult patients with a left ventricular ejection fraction ≥ 40% and negative CA screening (pyrophosphate single-photon emission computed tomography imaging and/or via a dedicated cardiac amyloidosis [CA] clinic) at our center from January 2018 to August 2023. H2FPEF and HFA-PEFF scores were calculated for each patient. Patients were subsequently categorized as high (both H2FPEF ≥ 6 and HFA-PEFF ≥ 5), intermediate (either H2FPEF ≥ 6 or HFA-PEFF ≥ 5), or otherwise indeterminate probability of HFnrEF. Baseline medical management and clinical outcomes at 1 year were recorded. Of the 302 patients included (43% women, mean age 74 years, body mass index 28.7 ± 6.8 kg/m2, N-terminal prohormone brain natriuretic peptide level 4640 ± 7877 ng/L), 25% were classified as high and 42% as intermediate HFnrEF probability. However, only half had a documented clinical diagnosis of HFnrEF. Among patients with high or intermediate probability, 6% were treated with sodium glucose transporter-2 inhibitors, 29% with mineralocorticoid receptor antagonists, and 43% with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. At 1-year follow-up, the heart failure hospitalization rate was 16% and mortality was 14% in this group. Two thirds of patients with negative CA screening had intermediate or high probability of HFnrEF based on H2FPEF and HFA-PEFF scores, which was also associated with a higher rate of adverse events. Using these scores in combination to prioritize patient referrals to dedicated HFnrEF clinics may lead to improved treatment and outcomes.